🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. Lapaquistat acetate and atorvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  2. Lapaquistat acetate and current lipid-lowering treatment

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  3. Lapaquistat acetate and rosuvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  4. Lapaquistat acetate and simvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  5. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  6. Levetiracetam XR, Masked Keppra® placebo film-coated tablets (a placebo tablet inside a capsule), Keppra 500 mg film-coated tablets, Levetiracetam prolonged-release placebo granules

    NEURAXPHARM AUSTRALIA PTY LIMITED

    Refractory Partial Onset Epilepsy

    phase 3 small molecule active

    1 trial

  7. Live Combined Bacillus Subtilis and Enterococcus Faecium Enteric-coated Capsules combined with Bortezomib+Dexamethasone/Bortezomib+Dexamethasone+Daratumumab/single Daratumumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immunoglobulin Light-chain Amyloidosis

    phase 3 small molecule active

    1 trial

  8. Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation Proctitis

    phase 3 small molecule active

    1 trial

  9. Lonsurf 15 mg/6.14 mg film-coated tablets, FRUZAQLA 1 mg hard capsules, Lonsurf 20 mg/8.19 mg film-coated tablets, FRUZAQLA 5 mg hard capsules

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic oeso-gastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  10. Lynparza 150 mg film-coated tablets, IBRANCE 125 mg hard capsules, Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Tabrecta 200 mg film-coated tablets, Daurismo 100 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, Tabrecta 150 mg film-coated tablets, Lytgobi 4 mg film-coated tablets, Mekinist 2 mg film-coated tablets, IBRANCE 100 mg hard capsules, Tyverb 250 mg film-coated tablets, Tafinlar 75 mg hard capsules, Zykadia 150 mg hard capsules, IBRANCE 7

    The George Institute

    Unresectable locally advanced and/or metastatic soft-tissue sarcoma

    phase 3 small molecule active

    1 trial

  11. MIDAZOLAM , CEDACONDA 100 % V/V, liquide pour inhalation par vapeur, PROPOFOL

    Pari Pharma GmbH

    Adult patients with severe cardiogenic shock on venoarterial ECMO support for less than 24 hours.

    phase 3 small molecule active

    1 trial

  12. MITAPIVAT, MITAPIVAT, "Placebo to Match Mitapivat Tablets, 5 mg and 20 mg, are supplied as film-coated, blue, round tablets for oral administration Placebo to Match Mitapivat Tablets, 50 mg or 100 mg, are supplied as film-coated, blue, oblong tablets for oral administration. Placebo to Match Mitapivat Granules, 1 mg, are supplied as film-coated, white, round granules for oral administration", MITAPIVAT

    Lacuna Pharma Pty Ltd

    Anemia in subjects with sickle cell disease (SCD)

    phase 3 small molecule active

    1 trial

  13. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  14. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  15. MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab

    Amgen

    Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.

    phase 3 small molecule active

    1 trial

  16. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  17. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    3 trials

  18. Mavorixafor, Mavorixafor Placebo Capsules

    X4 Pharmaceuticals, Inc

    Neutropenias

    phase 3 small molecule active

    1 trial

  19. Methylprednisolon acis 250 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Ocrevus 300 mg concentrate for solution for infusion, Gilenya 0.25 mg hard capsules, Placebo for FINGOLIMOD, Placebo for Ocrelizumab, Gilenya 0.25 mg hard capsules, Reisetabletten AL Dimenhydrinat 50 mg pro Tablette, Methylprednisolon acis 1000 mg Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung, Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 167 mg, Mexiletine granules for prolonged-release oral suspension 500 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  21. MiLES

    Turn Therapeutics

    Cancer

    phase 3 other active

    1 trial

  22. Microcrystalline cellulose, Sodium Chloride, Magnesium Stearate, MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  23. Mimetic granules of Yiqi-Wenjing prescriptions

    The First People's Hospital of Lianyungang

    Chemotherapy-induced Peripheral Neuropathy

    phase 3 small molecule active

    1 trial

  24. Mipomersen

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources